Abstract Objective To assess the efficacy of golimumab (GLM) as a treatment option for juvenile idiopathic arthritis (JIA)-associated uveitis refractory to adalimumab (ADA). Methods Retrospective single-centre study including patients with JIA receiving GLM for active uveitis after failing ADA. JIA- and uveitis-related data. including intraocular inflammation. https://www.roneverhart.com/La-Tierra-de-Acre-Mezcal-Espadin-86-proof/